The use of an immunosuppressive therapy known as tocilizumab, approved to treat the indication of rheumatoid arthritis, has been tested a number of times at this point involving numerous COVID-19 scenarios. Recently, the results of a study published in the New England Journal of Medicine reveal that this recent study investigating the use of the drug on patients with COVID-19-related pneumonia reveals that the monoclonal antibody failed to evidence significantly better clinical status or lower mortality in this particular patient cohort based on the findings in the COVACTA trial. Yet also released recently were results from the UK’s RECOVERY study, revealing that tocilizumab in that study offered a slight significantly statistical advantage to those COVID-19 patients experiencing low oxygen levels with significant inflammation.
Indicated for rheumatoid arthritis as an immunosuppressive therapy, the drug is also used to treat both systemic juvenile idiopathic arthritis and polyarticular juvenile idiopathic arthritis. With the trade name Actemra, the humanized monoclonal antibody targeting interleukin-6 receptor (IL-6R) was tested in COVID-19 cases as IL-6 is a cytoki...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).